ConsoneAI

ConsoneAI is a pioneering London-based TechBio startup applying artificial intelligence to de-risk and accelerate drug discovery through advanced toxicity prediction. Its flagship product, DioScor, utilizes bespoke deep learning models trained on a vast, curated database of over 80,000 chemical compounds to forecast toxicological outcomes across species and specific demographics. The company aims to address the high failure rate of drug candidates due to safety issues, support the industry's 3Rs (Reduce, Replace, Refine) commitment to animal welfare, and streamline regulatory submissions. Founded by a team with pharmaceutical industry experience, ConsoneAI positions itself at the intersection of ethical innovation and computational efficiency in preclinical development.

DioScor: An AI-powered platform that uses bespoke deep learning models trained on a proprietary database of 80k+ chemical compounds to predict organism-level toxicity outcomes across species and demographics.

ConsoneAI competes in the growing AI-for-drug-discovery space against well-funded public and private companies like Exscientia, Recursion, and Insilico Medicine, which often have broader discovery platforms. It also competes with traditional preclinical contract research organizations (CROs) and in-house pharma capabilities, differentiating itself with a sharp focus on organism-level toxicity prediction and the 3Rs mandate.